Drug Profile
Research programme: myotonic dystrophy therapeutics - Biogen/Ionis Pharmaceuticals
Alternative Names: DM1 antisense therapeutic; DMPK antisense compoundLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Biogen; Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myotonic dystrophy
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Myotonic dystrophy in USA
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
- 11 Oct 2013 Preclinical development is ongoing in USA